ERBB2 and breast carcinoma: T-DXd and SG are two more recently approved ADCs for the treatment of different solid tumors, including advanced breast cancer (Narayan et al., 2021; Wahby et al., 2021), advanced gastric, or gastroesophageal junction cancer (Shitara et al., 2020), pretreated metastatic HER2-mutant NSCLC (Li et al., 2022), or advanced urothelial cancer (Tagawa et al., 2021).